Despite early access friction, Bimzelx’s clinical promise and prescriber satisfaction suggest long-term opportunity in PsA and axSpA. Exton, PA., June
High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.
Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing
Products such as Tarpeyo (Calliditas), Filspari (Travere) and now Novartis’ Fabhalta and Venrafia provide physicians more options than ever before.
US hematologists express growing confidence in curative gene therapies such as Casgevy and Lyfgenia, while also showing heightened enthusiasm for
The ACR’s updated lupus nephritis treatment guidelines emphasize triple therapy regimens anchored by Benlysta or a calcineurin inhibitor, while Gazyva’s
Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists EXTON, PA, April
Dermatologists rely heavily on topical therapies for cutaneous lupus erythematosus (CLE), but are increasingly interested in systemic agents with user-friendly
Rheumatologists and dermatologists highlight Saphnelo, Sotyktu, and litifilimab as leading candidates to address unmet needs in CLE patients, particularly those
Recently released research reveals key insights into physician perspectives, practice management changes, and expected prescribing changes resulting from recent IRA-driven
Spherix’s inaugural Patient Dynamix™: IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care
Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global
